International conference in Barcelona attracts world-class research from
WINNIPEG, Oct. 7, 2013 /CNW/ - Canadian researchers will deliver some 24
presentations in Barcelona, Spain this week during AIDS Vaccine 2013 -
the largest and most diverse international conference of researchers,
advocates, clinicians, private sector partners and public health
experts working collaboratively to advance HIV vaccine discovery.
Canadian researchers, including many new investigators, will come from
across the nation to present their findings on HIV vaccine related
subjects, such as mucosal immunity, dendritic cell-based immunotherapy,
and DNA vaccines. Among the researchers are five AIDS Vaccine 2013
conference scholarship recipients.
"We are pleased to see so many new and early career investigators from
Canada participating in AIDS Vaccine 2013," says Greg Hammond, director
of the Canadian HIV Vaccine Initiative (CHVI) Research and Development
Alliance Coordinating Office (ACO). "Supporting Canadian researchers
and the AIDS Vaccine Conferences are some of the key functions of the
CHVI, which was established by the Government of Canada and the Bill &
Melinda Gates Foundation. The CHVI is also focused on building and
facilitating national and international collaborations through a
network called the CHVI Research and Development Alliance."
"We have some great new investigators in training, and they are among
our strengths in the Canadian research community," says Simon Fraser
University Associate Professor and Canada Research Chair Mark Brockman,
who is a principal investigator funded through the CHVI.
Brockman says it is important for graduate and post-doctoral students to
attend conferences like AIDS Vaccine 2013 so they can build
international linkages early in their careers. "Networking should be
ongoing for graduate and postdoctoral students as it can result in
strong ties for the future. Large, international collaborative teams
make sense in HIV vaccine research because developing an effective
vaccine will require knowledge and skills beyond one group."
Brockman's own research has for many years hinged on building
international, cross-disciplinary collaborative teams from Canada and
Africa. "A lot of Canadian groups are well positioned in Africa, with
research teams in Kenya, Uganda, Botswana, and South Africa to name a
With over 65 projects funded through the CHVI since its inception in
2007, 18 involve African collaborations where Canadian-based
researchers work closely with peers in Africa.
"Canada's strengths are in its international collaborations," Hammond
says. "We are well poised to make an important contribution to
advancing HIV vaccines and the next generation of researchers are
crucial to that endeavour."
The CHVI is a five-year collaborative initiative between the Government
of Canada and the Bill & Melinda Gates Foundation, and represents a
significant Canadian contribution to global efforts to develop a safe,
effective, affordable and globally accessible HIV vaccine. The ACO was
established by the Government of Canada and the Bill & Melinda Gates
Foundation in 2011 at the International Centre for Infectious Diseases
(ICID), a not-for-profit, non-governmental organization based in
Winnipeg, Manitoba. The ACO is funded by the Public Health Agency of
SOURCE: Alliance Coordinating Office
For further information:
Communications Specialist, Alliance Coordinating Office
International Centre for Infectious Diseases